EUVIMEDEUVIMED entdecken
Crossref

Orosomucoid Enhances Insulin Sensitivity via the C–C Chemokine Receptor Type 5/Protein Kinase B Axis

Pengyuan Wang, Yang Sun, Xia Liu iD

Experimental and Clinical Endocrinology & Diabetes · 01.10.2026

DOI: 10.1055/a-2958-3521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 01.10.2026. Verfasst von Pengyuan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Naval Medical University, Department of Clinical Pharmacy, School of Pharmacy, China, Shanghai. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Shanghai Science and Technology Innovation Action Plan, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insulin resistance is a central pathological feature underlying various metabolic disorders, involving complex mechanisms and multi-organ dysfunction. This study investigates the role of the acute-phase protein orosomucoid in systemic glucose homeostasis. This study utilized high-fat diet–induced obese mice to model insulin resistance. The genetic deletion of orosomucoid 1 was applied, and the metabolic effects of exogenous orosomucoid administration were examined. Molecular analysis included assessing protein kinase B phosphorylation. The dependency of observed benefits on specific receptors was tested using pharmacological inhibition of C–C chemokine receptor type 5 and evaluation of the leptin receptor’s role. We demonstrate that genetic deletion of orosomucoid 1 induces insulin resistance, whereas exogenous orosomucoid administration improves glucose tolerance and insulin sensitivity in high-fat diet mice. At the molecular level, orosomucoid augments insulin-induced protein kinase B phosphorylation. Notably, these metabolic benefits are independent of the leptin receptor but are critically dependent on the C–C chemokine receptor type 5, as demonstrated by pharmacological inhibition. Our findings establish orosomucoid as an endogenous insulin sensitizer via the C–C chemokine receptor type 5/protein kinase B pathway, coordinately ameliorating insulin resistance across multiple metabolic organs and highlighting its therapeutic potential as a novel target for metabolic disorders.

Autor:innen und Institutionen

  • Naval Medical University, Department of Clinical Pharmacy, School of Pharmacy, China, Shanghai.
  • No. 981 Hospital of the PLA, Department of Gastroenterology, Hebei, China, Chengde.

ORCID-Profile: Xia Liu

Förderung

  • Shanghai Science and Technology Innovation Action Plan
  • National Natural Science Foundation of China

Zitieren

APA

Wang, P., Sun, Y., & Liu, X. (2026). Orosomucoid Enhances Insulin Sensitivity via the C–C Chemokine Receptor Type 5/Protein Kinase B Axis. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/a-2958-3521

Vancouver

Wang P, Sun Y, Liu X. Orosomucoid Enhances Insulin Sensitivity via the C–C Chemokine Receptor Type 5/Protein Kinase B Axis. Experimental and Clinical Endocrinology & Diabetes. 2026. doi:10.1055/a-2958-3521

BibTeX
@article{Wang2026,
  author = {Wang, Pengyuan and Sun, Yang and Liu, Xia},
  title = {Orosomucoid Enhances Insulin Sensitivity via the C–C Chemokine Receptor Type 5/Protein Kinase B Axis},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2026},
  doi = {10.1055/a-2958-3521}
}
Kostenlos starten →